No Data
No Data
Pharma Block Sciences (300725.SZ): As of July 10th, the company has 33,580 shareholders.
Pharma Block Sciences (300725.SZ) stated on the investor interaction platform on July 17th that as of July 10th, 2024, the number of shareholders in the company was 33,580.
We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt
PharmaBlock Sciences (Nanjing) (SZSE:300725) Sheds CN¥445m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
Pharma Block Sciences (300725.SZ) annual equity distribution for 2023: 3.1 yuan per 10 shares, with stock registration on June 13.
Pharma Block Sciences (300725.SZ) announced that the company's annual equity distribution plan for 2023 is: based on the company's current...
Pharmaceutical Stone Technology (300725.SZ): The repurchase was completed with a cumulative cost of 30.25,700 yuan to repurchase 836,09 million shares
Gelonghui, May 30, 丨 Pharmaceutical Stone Technology (300725.SZ) announced that as of May 30, 2024, the company had repurchased a total of 836,009 shares through a dedicated securities account, accounting for 0.4187% of the company's total share capital. The highest transaction price was 46.00 yuan/share, the minimum transaction price was 24.63 yuan/share, and the payment amount was 30.257 million yuan (not including transaction fees). The company has completed the implementation of this repurchase plan.
Pharmaceutical Stone Technology (300725.SZ): Revenue from foreign customers accounted for 68.48% in 2023
Gelonghui, May 9丨Pharmaceutical Stone Technology (300725.SZ) said on the investor interactive platform that our products and services are mainly used in pharmaceutical companies' new drug research and development projects. Judging from the global innovative drug development pattern, overseas companies dominate, so the company's revenue mainly comes from overseas. In 2023, revenue from foreign customers accounted for 68.48%.
No Data